Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests-Reference-Cited by-同舟云学术

Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests

Published:2021-11-15 Issue: Volume: Page:
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Johnson Amy L.¹²^ORCID,Hayward Kelly L.¹²^ORCID,Patel Preya³⁴,Horsfall Leigh U.¹²,Cheah Alvin Ee Zhiun²,Irvine Katharine M.¹⁵,Russell Anthony W.⁶⁷,Stuart Katherine A.²,Williams Sue⁸,Hartel Gunter⁹,Valery Patricia C.¹⁹^ORCID,Powell Elizabeth E.¹²

Affiliation:

1. Centre for Liver Disease Research Faculty of Medicine University of QueenslandTranslational Research Institute Woolloongabba QLD Australia

2. Department of Gastroenterology and Hepatology Princess Alexandra Hospital Woolloongabba QLD Australia

3. Institute for Liver and Digestive Health University College London Division of Medicine London United Kingdom

4. The Liver Unit Newcastle Upon Tyne Hospitals National Health Service Foundation Trust Newcastle upon Tyne United Kingdom

5. Mater Research University of QueenslandTranslational Research Institute Woolloongabba QLD Australia

6. Faculty of Medicine University of Queensland Brisbane QLD Australia

7. Department of Diabetes and Endocrinology Princess Alexandra Hospital Brisbane QLD Australia

8. Inala Primary Care Inala QLD Australia

9. QIMR Berghofer Medical Research Institute Herston QLD Australia

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1852

Reference23 articles.

1. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics;Polyzos SA;Metabolism,2019

2. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta‐analysis;Younossi ZM;J Hepatol,2019

3. Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease;Angulo P;Gastroenterology,2015

4. Noninvasive biomarkers in NAFLD and NASH ‐ current progress and future promise;Wong VW;Nat Rev Gastroenterol Hepatol,2018

5. Nonalcoholic fatty liver disease burden: Australia, 2019‐2030;Adams LA;J Gastroenterol Hepatol,2020

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis;Seminars in Liver Disease;2024-07-09

2. Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver disease;Hepatology Communications;2024-07

3. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD;Journal of Hepatology;2024-05

4. AST to ALT ratio as a prospective risk predictor for liver cirrhosis in patients with chronic HBV infection;European Journal of Gastroenterology & Hepatology;2024-01-22

5. The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study;International Journal of Hepatology;2024-01-17